Serve You Rx teams with Pear to lead access to prescription digital therapeutics (PDTs) with proven outcomes in treating substance use disorder (SUD) and opioid use disorder (OUD) and to support ...

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today ...

Over 12 weeks, using reSET-O in addition to treatment as usual lowered costs by $1,014 and added 0.003 quality-adjusted life years compared with normal treatment alone. Treatment as usual was ...

Pear Therapeutics Inc. released nine-month, real-world data showing long-term reduction in costly health care utilization categories, including inpatient stays and emergency department visits, in ...

Out of a group of 3,817 people who completed a 12-week prescription of reSET-O, 643 were prescribed a refill of another 12 weeks. For those who completed a total of 24 weeks of treatment, abstinence ...

BOSTON & EAGAN, Minn.--(BUSINESS WIRE)--More than 20 million Americans struggle with drug addiction while only 10-20% receive treatment. 1 Prime Therapeutics LLC (“Prime”) and Pear Therapeutics, Inc. ...

Alcohol is the most common substance use disorder (SUD), representing 70% of the more than 40 million people with SUD1 The real-world observational study evaluated 548 patients with alcohol-related ...

Pear Therapeutics may be gone, but one of its most important deals is still driving critical conversations about how medical apps can find a foothold in the slow-moving health care system. In recent ...

Pear Therapeutics Inc. released nine-month, real-world data showing long-term reduction in costly health care utilization categories, including inpatient stays and emergency department visits, in ...